ResMed Share Price Hits another Record High Ahead of Quarterly Report

By ,

Shares in ResMed Inc [ASX:RMD] are now sitting steady at $16.55, rising 1.16% today. This week saw the medical specialist group hit a record high in its share price ahead of the release of their Q2 results for 2019 — due Friday, 25 January.

ResMed is a Californian health and sleep device company specialising in the treatment of various sleep disorders. They currently produce a range of products designed to treat sleeping problems including sleep apnoea and chronic obstructive pulmonary disease.

Why this is a big deal for companies like ResMed?

Despite being in such a niche market, ResMed have made every effort to define themselves as the leaders in their industry. Shares in ResMed have outperformed others in the med-tech industry, with a 48% rise against an overall 2% decline on the ASX.

ResMed’s share position in the US and in Australia more than likely comes down to the growing market for new medical devices, which companies like Sigma Healthcare Limited [ASX:SIG] and Healius Limited [ASX:HLS] have also taken advantage of:

Rising healthcare expenditures, increasing obesity and unhealthy lifestyle practices along with expanded treatment options are anticipated to continue driving demand for sleep apnea devices.’

Over the past year, ResMed have contributed to their growing revenue base by expanding their products portfolio and shifting their focus toward the digital software space.

What’s the prognosis for Q2 2019?

Given this long-term outlook (and the fact ResMed have already benefited from strong earnings growth in 2018), earnings from Friday’s trade update are forecast to be around US$0.92 a share.

The market seems to see the potential in ResMed following a stream of product upgrades and market acquisitions. Given the extent of sleep-related disorders globally, it may be that investors expect this potential to continue into 2019.


Ryan Clarkson-Ledward,
For Money Morning

PS: Excited about the growth in healthcare stocks? Find out how you can get in on these high-risk tech plays with massive potential. Read Harje Ronngard’s free reportThe key to Spotting Breakout Biostocks’ here for free.

About Ryan Clarkson-Ledward

Ryan Clarkson-Ledward is an Editor at Money Morning.

Ryan holds degrees in both communication and international business. He helps bring Money Morning readers the latest market updates, both locally and abroad. Ryan tackles all the issues investors need to know about that the mainstream media neglects.

Ryan is also the Editor…

RMD Shares Down: Market Open before Recouping Grounds (ASX:RMD)

Shares in Resmed CDI (ASX:RMD) are down 0.6% at time of writing, slipping as investors digest the medtech’s fourth quarter results.

Weekly ASX Market Wrap — WSA and SAR Top Movers Last Week

The previous week saw the ASX All Ordinaries [XAO] close at 6,011 points. The opening three days of the week saw trading move sideways before a drop on Thursday. Friday was a wild day of trading, with [XAO] eventually…

The ResMed Share Price Up on Results (ASX:RMD)

San Diego-based healthcare company ResMed Inc [ASX:RMD] has seen a 16% increase in year-over-year revenue to $769.5 million. The ResMed share price is up 5.47% to $24.68 at the time of writing…

ResMed Share Price Rises on Another Strong Quarter (ASX: RMD)

The ResMed share price added $2.70 to their price within the first hour of trading — a 14.5% spike. Shares of global health company ResMed Inc [ASX:RMD, NYSE:RMD] will pique investor interest today as they announce their Q1 FY 2020 results…

ResMed Shares Climb 10% with Strong Q3 Results

World-leading connected health company ResMed Inc [ASX:RMD] is a frontrunner in today’s trading, with their shares up 10.4% at time of writing, to $16.34 per share.